Those who study blastic plasmacytoid dendritic cell neoplasm (BPDCN) struggle to make dermatologists and others aware that the rare hematologic malignancy that often first presents with skin manifestations exists.
Tagraxofusp, the first and only FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm (BPDCN), outperforms traditional chemotherapy treatment for the rare myeloid malignancy.
The 10-year-old male presented after experiencing five months of bilateral knee joint pain. A bone marrow smear and biopsy revealed the boy had blastic plasmacytoid dendritic cell neoplasm. Doctors treated him and the patient achieved complete remission. The patient presented with a scalp rash one month after his first complete remission.